

# Spectrum of Gastric Carcinoma in a Tertiary Care Centre with Special Reference to PDL1 and Cyclin D1

## ABSTRACT

**Introduction:** Gastric carcinoma is the fifth most frequently diagnosed tumor and the fourth leading cause of death. They represent a heterogeneous group of tumors with multifactorial etiologies, both environmental and genetic. PD-L1 is a transmembrane protein, and a positive PD-L1 expression in gastric carcinoma may be a predictive biomarker of the response to PD-1/PD-L1 immune checkpoint inhibitors. Cyclin D1 is an important cell cycle regulatory protein and involved in the carcinogenesis of various cancers including gastric cancer.

**Aims:** The aim of this study is to find out the clinicopathological spectrum of gastric carcinoma and to show the immunohistochemical expression of Cyclin D1 and PD-L1 to evaluate their prognostic importance and their therapeutic impact.

**Study Design :** It is an observational cross-sectional study conducted in the Department of Pathology in collaboration with the Department of Surgery, in a tertiary care hospital. Partial and total gastrectomies were selected from January 2021 to July 2022 in a tertiary care hospital. Clinical history was collected in the study proforma. Immunohistochemical staining for Cyclin D1 and PD-L1 was performed.

**Material and Methods :** The clinicopathological parameters like age, gender, histological type, regional lymph node status, lymphovascular invasion, perineural invasion, and pathological stage were compared and correlated with Cyclin D1 and PD-L1 expression.

**Results:** positive Cyclin D1 and PDL1 expression were found in 50% and 70% cases of gastric carcinoma, respectively. Cyclin D1 expression showed statistically significant correlation with anemia, regional lymph node status, and lymphovascular invasion. PD-L1 and Cyclin D1 expression showed statistically significant association between them (p value-0.0006).

**Conclusion:** Cyclin D1 and PDL1 are important biomarkers in gastric carcinoma. Their contribution towards prediction of progression and prognosis, along with newer therapeutic

modalities, is of immense importance in these patients. A statistically significant correlation was found between these two markers.

**Keywords :** *Combined Positive Score, Cyclin D1, gastric carcinoma, gastrectomy, Immunohistochemistry, PD-L1,*

## Introduction

“Gastric carcinoma (GC) is one of the most common cancers with mortality and morbidity worldwide”<sup>[1]</sup>. “Men are twice as commonly affected as women. This may be due to the protective effect of oestrogen against gastric cancer development”<sup>[2]</sup>. “GC is a multifactorial disease, 90% of which are sporadic, while 10% of the cases are familial. The genetic factors are usually the primary cause of Hereditary diffuse gastric cancer”<sup>[3]</sup>. “The GC is one of the common cancers in the north eastern and southern states of the Indian subcontinent, as per the National Cancer Registries. Its frequency in the north eastern states of India is higher than the rest of India”<sup>[4]</sup>.

“The incidence shows a wide geographical variation, with more than 50% of the new cases occurring in the developing countries. Carcinoma stomach is the 5<sup>th</sup> common cause of carcinoma in the world. and 4<sup>th</sup> common cause of carcinoma death. It is very common in Asia, in China, Japan, Korea, etc. Previously, it was frequent in the United States and Europe, but its incidence has decreased in these countries”<sup>[5]</sup>.

“Adenocarcinoma is the major histological subtype of GC, constituting 90-95% of all gastric malignancies. Environmental factors play a vital role in the incidence of GC, reflecting a characteristic geographical distribution”<sup>[5]</sup>. Death from stomach carcinoma is more frequent in Eastern Asia, South America, and parts of Europe.<sup>[5]</sup>

“Helicobacter pylori (H. pylori) infection and certain environmental factors like consumption of preserved food containing carcinogenic nitrates, lifestyle, tobacco, alcohol, and obesity are some of the known etiologic factors for GC”<sup>[5]</sup>. There is a general declining

incidence of GC mainly due to higher standards of hygiene, improved food conservation, and *H. pylori* eradication. GC historically ranks among the worst malignancies, with 20%-30% of the patients surviving for 5 years after diagnosis. There is some improvement in survival in Japan, Korea, and to some extent in China<sup>[5]</sup>.

PD1 is expressed in lymphocytes and in various tumor cells. If the interaction between Programmed Death 1 (PD1) and Programmed Death Ligand 1 (PDL1) can be stopped by anti PDL1, the antitumor response occurs<sup>[6-7]</sup>.

Accumulation of genetic and molecular abnormalities occurs during the process of gastric carcinogenesis, in which oncogenes are activated, tumor suppressor genes, and DNA repair genes are inactivated. Overexpression of growth factor receptors, inactivation of DNA repair genes, and cell adhesion molecules also occur in this process<sup>[8-9]</sup>. The Cyclin D1 is increased in cases of gastric adenocarcinoma. Its overexpression is also related to the prognosis and overall survival of the patients. It is usually found in poorly differentiated tumors and related to decreased survival of the patients<sup>[10]</sup>.

PDL1 is also assessed in cases of gastric carcinoma. It has an important therapeutic role. On the basis of PDL1 positive cells CPS (Combined Positive Score) is assessed, and therapy is started<sup>[11]</sup>. PDL1 expression was higher in adenocarcinoma and invasive carcinoma, and in those cases the diameter of the lesion in the gross specimen is more than 5 cm<sup>[12]</sup>. The combined study of gastric carcinoma and its association with Cyclin D1 and PDL1 are lacking. We undertook this study to ascertain the relationship among Gastric carcinoma, PDL1, and Cyclin D1. Immune checkpoint inhibition plays an important role in modern oncology. The PD-1 (Programmed Death 1) receptor and its ligand PD-L1 (Programmed Death ligand 1) are physiologically involved in immunomodulation. PD-1, a member of CD 28 superfamily, is an important immunosuppressive molecule, mainly expressed in T cells, NK cells and B cells surrounding tumor tissues. PD-L1 is a 40 kDa type 1 transmembrane protein and is a member of the B<sub>7</sub> protein family, which are expressed on a variety of cell types, including epithelium, B cells, mesenchymal stem cells, dendritic cells, macrophages, and mast cells<sup>[13]</sup>. Immune checkpoint inhibitors targeting PD1/PDL1 can aid the treatment of Gastric adenocarcinoma (GAC). However, the reported positive expression rate of PD-L1 in GAC is variable<sup>[14,15]</sup>.

“The Cyclin D protein family interacts with cyclin dependent kinases (CDKs) 2,4, and 6 to regulate cell cycle progression. Cyclin D1, Cyclin D2, and Cyclin D3 are the three isoforms identified in humans. Cyclin D1 is a cell cycle regulator frequently involved in the G1/S transition. Deregulation of this pathway can result in aberrant cell cycle, resulting in carcinogenesis”<sup>[16,17]</sup>.

## Material and Methods

It is an observational cross-sectional study conducted in the Department of Pathology in collaboration with the Department of Surgery, in a tertiary care hospital. Fifty patients of Primary Gastric carcinoma diagnosed on partial and total gastrectomies were selected. The study was conducted over a period of 18 months from January 2021 to July 2022. Patients who received neo-adjuvant systemic therapy were excluded from this study.

Total 798 blocks were made from the specimens. After fixation, grossing was done. Different types of carcinoma were noted ( Fig. 1 A,B,C ). From the paraffin blocks, Hematoxylin & Eosin (H&E) and Immunohistochemical (IHC) staining were done for Cyclin D1 and PD-L1 expression in all these cases.

Four- micron sections were prepared from each formalin fixed and paraffin embedded tissue sample and stained with H&E and antibody against PD-L1( monoclonal Mouse anti human PD-L1, clone 22C3, DAKO, LOT-11431000, Expiry date: 1/05/2024) and Cyclin D1(monoclonal rabbit anti-human, clone EP12, DAKO, LOT-R07035MA, Expiry date: 31.5.2024). Normal tonsil used as positive control and negative control was achieved by omission of primary antibody in PD-L1 and Cyclin D1.

## Interpretation of immunostaining

**PD-L1:** PD-L1 expression was evaluated using Combined Positive Score (CPS).

CPS = [Number of PD-L1 stained cells(tumor cells, lymphocytes, macrophages)/Total number of viable tumor cells] x100

Maximum CPS score is 100. A minimum of 100 viable tumor cells must be present

for the specimen to be considered adequate for PD-L1 evaluation.

PD-L1 expression was considered positive for tumor cells if tumor cells showed complete and/or partial circumferential linear cellular membrane staining (brown) of any intensity where astumor associated immune cells are considered PD-L1 positive if there is any staining (brown).

Results were considered PD-L1 negative if CPS was  $<1$  and PD-L1 positive if CPS was  $\geq 1$ .

### **Tumor infiltrating lymphocytes (TILs):**

Tumor infiltrating lymphocytes (TILs) are globally defined as the mean percentage of the invasive tumor area (including the tumor bed and peri-tumoral stroma), occupied by lymphocytes and plasma cells

Based on this definition, the tumors included in this study were divided into three grades

Grade 1-(low,  $\leq 10\%$ ), considered TILs- low.

Grade 2-(moderate, 10-50%)

Grade 3-(high,,  $>50\%$ )

Patients with Grade 2 or 3, were considered TILs high

### **Cyclin D1:**

Cyclin D1 immunohistochemical intensity and distribution were semi-quantitatively scored using the Allred score method. Only nuclear staining was considered specific. With this method, the intensity of immunohistochemical reaction as viewed under a light microscope (10 visual fields under high power objective, 400x) was recorded as 0 (negative); 1 (weak) ; 2 (moderate); and 3 (strong). The proportion of positive cells and intensity scores were then added to obtain a total score, which ranged from 0 to 8.

### **Statistical Analysis**


All data were thoroughly maintained on a Microsoft Excel spreadsheet. Statistical analyses were performed using SPSS (software version 27.0; SPSS Inc.; Chicago, IL, USA) and Graph Prism

version 5. The P value was found using a table of values from the Student's t-distribution. P value  $\leq 0.05$  was considered statistically significant.

## Results

There were a total 50 cases, which includes 36 males and 14 females. The age of patients ranged from 31 to 80 years; the mean age (+/- standard deviation) of the patients was 55.0 +/- 11.76 years. The predominant age group (52%, 26 cases) is 41-60 years. The antral and pyloric region were most frequently involved (52% and 38%, respectively). The most common symptoms were dyspepsia, vomiting, and weight loss, and predisposing factors were unhealthy food habits followed by smoking. The size of the tumors ranged from 1.5 cm to 8 cm. More than 50% of cases (29 cases -58%) were in T3 in the TNM group.

There were 22 cases (44%) of Tubular adenocarcinoma (the most common histological subtype) ( Fig.1 D,E ) followed by 10 cases (20%) of Poorly cohesive carcinoma ( Fig.1 F,G). 8 cases (16%) of Mucinous adenocarcinoma (Fig.1H), 5 cases (10%) of Mixed adenocarcinoma, 4 cases (8%) of Poorly cohesive carcinoma-signet ring cell type and 1 case of Mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN) (Fig.1 H,I) . Intestinal type was the most prevalent Lauren's histological type (60%). Regional lymph nodes were involved by the tumor cells in 32 cases (64%) (Fig.1 K). Lymphovascular invasion was present in 41 cases (82%). Perineural invasion was present in 14 cases (28%). 19 cases (38%) had Grade 1, 26 cases (52%) had Grade 2, and 5 cases (10%) had Grade 3 TILs (Fig.1 L).



**Fig.1 :**

Gross pictures of gastrectomy specimens showing, A. an ulcero-proliferative growth in the antro-pyloric region of stomach, B. a mucinous growth and C. a polypoid growth in the body of stomach. H&E (400X) from growth in stomach showing, D. well differentiated gastric adenocarcinoma, E. moderately differentiated gastric adenocarcinoma, F. poorly cohesive carcinoma (other cell type), G. poorly cohesive carcinoma (signet ring cell type), H. mucinous adenocarcinoma, I. mixed tubular and poorly cohesive carcinoma. H&E (100X) from growth in stomach showing, Gastric MiNEN. H&E (400X) showing K. lymph node metastasis from gastric adenocarcinoma and L. tumor infiltrating lymphocytes in a case of gastric adenocarcinoma.

On Cyclin D1 immunohistochemical examination, 25 cases were Cyclin D1 negative (score 0 to 2) and 25 cases were Cyclin D1 positive (score 3 to 8) among which 7 cases

had Cyclin D1 score 5 (moderate), 13 cases had Cyclin D1 score 6 (strong) and 5 cases had Cyclin D1 score 7 (strong) (Fig.2 A,C,E,H,J).

On PD-L1 immunohistochemical examination, 15 cases were PD-L1 negative (CPS <1), 35 cases were PD-L1 positive (CPS >=1). Among PD-L1 positive cases, 20 cases had CPS between 1 to 4, 5 cases had CPS between 5 to 9 and 10 cases had CPS >= 10 (Fig.2 B,D,F,G,I,K,L)




Fig.2:

Immunohistochemistry done in various subtypes of gastric adenocarcinoma showing A. (400X) Cyclin D1 expression in well differentiated gastric adenocarcinoma, B. (400X) PD-L1 expression in well differentiated gastric adenocarcinoma, C. (400X) Cyclin D1 expression in moderately differentiated gastric adenocarcinoma, D. (400X) PD-L1 expression in moderately differentiated gastric adenocarcinoma, E. (400X) Cyclin D1 expression in poorly cohesive carcinoma (other cell type), F. (400X) PD-L1 expression in poorly cohesive carcinoma (other cell type), G. (400X) PD-L1 expression in poorly cohesive carcinoma (signet ring cell type), H. (400X) Cyclin D1 expression in mucinous adenocarcinoma, I. (100X) PD-L1 expression in mucinous adenocarcinoma, J. (400X) Cyclin D1 expression in mixed tubular and poorly cohesive carcinoma, K. (400X) PD-L1 expression in mixed tubular and poorly cohesive carcinoma, and L. (400X) PD-L1 staining tumor infiltrating lymphocytes in gastric adenocarcinoma.

PD-L1 showed statistically significant correlation with anemia (p value-0.0117), TILs (p value-0.0021), lymph node status (pvalue-0.0007), lymphovascular invasion (p value-0.0080), Pathological stage (0.0111).

No statistically significant correlation was found between PD-L1 expression and age of patients, gender of patients, clinical features (other than anemia), predisposing factors, tumor location, tumor size, gross features, Lauren's classification, and histological subtype. Among histological subtypes, Tubular adenocarcinoma (moderately differentiated) showed maximum positive PD-L1 expression (15 cases), followed by poorly cohesive carcinoma-other cell type (8 cases). Out of 8 cases of Mucinous adenocarcinoma, 5 cases showed positive PD-L1 expression. Among 5 cases of Mixed adenocarcinoma, 3 cases showed positive PD-L1 expression. There was a single case of MiNEN, which was negative for PD-L1 expression. PDL1 positive gastric carcinoma cases were associated with high TIL (grade 2 and 3).

Out of 22 cases of tubular adenocarcinoma, 11 cases were Cyclin D1 (CCND1) positive. 4 cases of poorly cohesive signet ring cell type showed positive CCND1 expression. Among 10 cases of poorly cohesive carcinoma other cell type, 4 were positive for CCND1. 4 out of 8 cases of Mucinous adenocarcinoma showed positive Cyclin D1 expression. 2 out of 5 cases of Mixed adenocarcinoma showed positive Cyclin D1 expression. A single case of MiNEN was negative for Cyclin D1 expression.

Out of 30 cases of intestinal type, 15 cases were positive for Cyclin D1 expression, and 21 cases were positive for PD-L1 expression. Out of 14 cases of diffuse type, 8 cases were positive for Cyclin D1 expression, and 11 cases were positive for PD-L1 expression.

There was a statistically significant correlation between Cyclin D1 expression and age of patients (p value-0.0402), anemia (p value-0.0005), regional lymph node status (p value-0.0017), lymphovascular invasion (p value-0.0099), perineural invasion (p value - 0.0117), pathological stage (p value-0.0015).

There is a statistically significant association between PD-L1 and Cyclin D1 expression (p value-0.0006). The correlation between clinicopathological factors and Cyclin D1 and PD-L1 expression is summarised in Tables 1 and 2. Cyclin D1 score 5 (moderate), 13 cases had Cyclin D1 score 6 (strong), and 5 cases had Cyclin D1 score 7 (strong).

The relationship between Cyclin D1 and clinicopathological factors has been described in Table 1.

The relationship between PDL1 and Clinicopathological factors have been described in Table No.2.

**Table 1 : Correlation between Cyclin D1 expression and clinicopathological(CP) factors**

[WD – Well Differentiated, MD – Moderately Differentiated, PC CA – Poorly Cohesive Carcinoma

LVI- Lympho vascular invasion. PNI- Perineural invasion ]

CP parameters	Clinicopathological (CP) factors	CyclinD1 expression		p-value
		Negative(0-2)	Positive(3-8)	

		(n=25)	(n=25)	
1) Age Group (in years)	<=40 41-50 51-60 >=61	7 5 6 7	0 8 7 10	0.0402
2) Sex	F M	5 20	9 16	0.2077
3) Gross Tumor description	Type 1 Type 2 Type 3 Type 4	3 9 9 4	2 7 13 3	0.7244
4) Histologic Type	<ul style="list-style-type: none"> <li>• Tubular adenocarcinoma (WD)</li> <li>• Tubular adenocarcinoma (MD)</li> <li>• PC CA-Signet ring cell type</li> <li>• PC CA-Other cell type</li> <li>• Mucinous Adenocarcinoma</li> <li>• MiNeN</li> <li>• Mixed adenocarcinoma</li> </ul>	2 9 0 6 4 1 3	1 10 4 4 4 0 2	0.4248
5) Regional Lymph node status	Metaplastic Deposit Reactive Not found	10 13 2	22 3 0	0.0017
6) LVI	Absent Present	8 17	1 24	0.0099
7) PNI	Absent Present	22 3	14 11	0.0117
8) Pathological Stage	Ia Ib IIa IIb IIIa IIIb IIIc IV	3 3 13 4 2 0 0 0	0 0 4 4 8 5 1 3	0.0015

**Table 2 : Correlation between PDL1 expression and clinicopathological(CP) factors**

[WD – Well Differentiated, MD – Moderately Differentiated, PC CA – Poorly Cohesive Carcinoma

**LVI- Lympho vascular invasion. PNI- Perineural invasion ]**

CP parameters	Clinicopathological (CP) factors	PD-L1-CPS Score (CPS Score $\geq$ 1 $\rightarrow$ PD-L1+)		p-value
		<1 (n=15)	$\geq$ 1(n=35)	
1) Age Group (in years)	<=40 41-50 51-60 >=61	4 3 5 3	3 10 8 14	0.2185
2) 2) Sex	F M	3 12	11 24	0.4094
3) Gross Tumor description	Type 1 Type 2 Type 3 Type 4	3 5 6 1	2 11 16 6	0.3831
4) Histologic Type	<ul style="list-style-type: none"> <li>• Tubular adenocarcinoma (WD)</li> <li>• Tubular adenocarcinoma (MD)</li> <li>• PC CA-Signet ring cell type</li> <li>• PC CA-Other cell type</li> <li>• Mucinous adenocarcinoma</li> <li>• MiNeN</li> <li>• Mixed adenocarcinoma</li> </ul>	2 4 1 2 3 1 2	1 15 3 8 5 0 3	0.4283
5) TILs	Grade 1 Grade 2 Grade 3	1 10 4	18 16 1	0.0021
6) Regional Lymph node status	Metaplastic Deposit Reactive Not found	4 9 2	28 7 0	0.0007
7) LVI	Absent Present	6 9	3 32	0.0080
8) PNI	Absent Present	12 3	24 11	0.4094

9) Pathological Stage	Ia	3	0	0.0111
	Ib	2	1	
	IIa	8	9	
	IIb	1	7	
	IIIa	1	9	
	IIIb	0	5	
	IIIc	0	1	
	IV	0	3	

UNDER PEER REVIEW

## Discussion

GC is a disease with multiple outcomes that cannot be predicted by clinicopathological features alone. Consequently, the identification of molecular biomarkers that may allow further outcome stratification and treatment decisions is of critical importance. It is seen that elevated Cyclin D1 expression occurs in 50% cases of GC<sup>[18-19]</sup>. Cyclin D1 expression has been found to be associated with lymph node involvement, metastasis, poor prognosis, and lack of response to platinum treatment in gastric cancer. Cyclin D1 (CCND1) activation is induced by *H. pylori* infection in stomach<sup>[20]</sup>. Cyclin D1 overexpression can help tumor formation and facilitate metastasis. Inactivation of Cyclin D1 can help in control of cell division, cell migration, and metastasis and thus help in treatment.<sup>[21,22]</sup>

PDL1 expression depends on the diameter of the lesion, and the depth of invasion of gastric carcinoma, and anti PDL1 antibody can be used therapeutically.<sup>[23-25]</sup>

In our study, we have studied two molecular biomarkers, namely, Cyclin D1 and PD-L1 on 50 patients. Understanding of the molecular events and pathways can lead to the application of molecular pathology in prevention, early diagnosis, tumor classification, and therapeutic intervention. The patients in this study presented with a mean age of 55 years, which was similar to the mean age procured in the study conducted by Saha et al.<sup>[26]</sup>. In our study, 52% of GC was in the age range of 41 to 60 years, and no cases of GC were found below 30 years of age. Also, the ratio of the male to female ratio was 2.5:1 in this study, which was nearly similar to that seen in the study of Saha et al.<sup>[26]</sup>.

In our study, statistical correlation was found between age and Cyclin D1 expression (p value - 0.0402) which was contrary to the study of Gao et al<sup>[18]</sup>.

*H. pylori* infection has been reported to be an important risk factor for GC patients. Machinda-Montani et al., in their study, found a strong association of *H. pylori* infection and smoking with GC<sup>[27]</sup>. Lee and Derakhshan found smoking and non vegetarian food habits, salty food, pickled vegetables, and excess salt intake were strong independent risk factors for GCs<sup>[28,29]</sup>. In our study, 54% of the patients were smokers, and 12% of the cases were on alcohol. Most of the cases were on unhealthy diets, i.e., excess salt and low fibre diets and non-vegetarian food. Here, *H. pylori* infection status among the patients was not

studied separately. In our series, we did not find any statistical correlation between predisposing factors and PD-L1 and Cyclin D1 expression.

GC often produces nonspecific symptoms when it is superficial, although the majority of the patients may have nonspecific gastrointestinal complaints such as dyspepsia and anorexia. Some had dysphagia, reflux, fullness after a little meal, etc<sup>[30]</sup>. In our study too, the most common symptoms were dyspepsia (80%), vomiting (70%), and weight loss (70%). 60% of patients presented with anemia.

Non Cardia stomach carcinoma is more common in developing countries and cardia carcinoma is common in developed countries<sup>[31]</sup>. In our study, 52% of the tumors were present in the antrum, followed by the pyloric region (38%).

According to Jun. S Y Cyclin D1 overexpression indicates better prognosis in cases of small intestinal adenocarcinoma<sup>[34]</sup>. Peng Gao et al.'s studies showed that Cyclin D1 is expressed in early and late GC. This is negative in gastric polyps. They also noted that Cyclin D1 positive GC cases have a worse prognosis<sup>[18]</sup>. Some studies indicate that Cyclin D1 overexpression is present in 50% of GC. It is seen in poorly differentiated GC and results in poor prognosis<sup>[35,36]</sup>. In GC, Cyclin D1 forms a complex with CD kinase (CDK). This complex of Cyclin D1/CDK4/6 is target for therapy<sup>[37]</sup>. According to Shan et al. (2017), CCND1 (Cyclin D1) expression was significantly increased in gastric intestinal type of adenocarcinoma of GC<sup>[10]</sup>. In our study, out of 30 cases of intestinal type, 21 cases were positive for PD-L1 and 15 cases were positive for Cyclin D1, while out of 14 cases of diffuse type, 11 cases were positive for PD-L1 and 8 cases were positive for Cyclin D1.

In some studies, 57% Gastric tumors showed PDL1 positivity and 42% tumors were PDL1 negative<sup>[32]</sup>. In other studies there was 37.8% PDL1 positivity in gastric carcinoma. Xing et al noted that PDL1 is usually positive in non metastatic GC.<sup>[33]</sup>

There is a difference of opinion regarding the prognosis of PDL1 GC. It has been seen that PDL1 expression indicates better prognosis in GC<sup>[38]</sup>. Junttila et al. in their study, found that PD-L1 positive tumor cells seem to be slightly more common in intestinal types, and the prognosis of PDL1 positive GC patients is worse than that of PDL1 negative patients<sup>[39]</sup>.

Shen et al. and Burr et al. did not show any association between PDL1 and CD8+ lymphocytes<sup>[41,42]</sup>. In another study, it was found that CD8+ T cells influence tumor immunity by differentiating into cytotoxic T lymphocytes. CD8+ T cell infiltration has been shown to correlate with PD-L1 expression in tumor cells and stroma<sup>[43]</sup>. CD8+ T cell infiltration correlates with PD-L1 expression and poor prognosis in GC. Dislich et al., in their study also stated that PD-L1 positivity was associated with higher Tumor Infiltrating Lymphocyte (TIL) count, which also supported previous studies<sup>[44]</sup>. In our study also we have seen that PDL1 positive cases were associated with high TIL grades ( grade 2 and 3 ). So we experienced the positive correlation between PDL1 and density of TIL like other studies.

There are 55% to 65% PDL1 positivity in GC <sup>[45]</sup>. PDL1 positivity differs in resected samples and biopsy samples. Yamashita et al. found in their series PDL1 positive tumors 46% to 70% in the resected and biopsy specimens of GC respectively <sup>[46]</sup>. CPS score more than one was seen in 43.6% cases of GC was seen by Markiefka et al <sup>[47]</sup> In our study there was a statistically significant correlation between PD-L1 expression ( PD-L1 CPS score) and TIL (p value = 0.0021). In our study, we found PD-L1 positivity ( CPS  $\geq 1$ ) in 70% of the cases, which almost corroborated with the study of Yamashita et al.<sup>[46]</sup>

Thus, our study revealed the clinicopathological spectrum of GC and its association with Cyclin D1 and PD-L1 expression. Both Cyclin D1 and PDL1 are important prognostic markers and can be used to guide clinicians ~~regarded any~~ regarding targeted therapy.

## Conclusion

The tumor marker analysis may reflect the various stages of the carcinoma and may assist the Clinicians in the planning and monitoring of the treatment. One of the most intractable challenges in clinical treatment of GC is that only a part of GC patients get benefit from traditional chemical treatment strategy. There are other elements that also affect the clinical outcome.

Inhibition of Cyclin D1 using specific therapy is a novel gastric cancer therapy . PD1/PDL1 immune checkpoint inhibitor therapy also used for treatment. PDL1 is also an independent prognostic predictor. Emerging evidence concerning experimental investigations and clinical trials suggested promising application of PD1/PDL1 blockade in these malignancies.

(PD-1) and its ligand Programmed death ligand 1 (PD-L1) cause immunomodulation by T cell inactivation and progression of cancer. So blocking the PD1/PDL1 pathway is helpful for control of GC and many other solid tumors.

### **Ethical Approval:**

The approval for this study was obtained from the Institutional Ethics Committee.

### **CONSENT**

Written informed consents were obtained from the patients for publication of this article and accompanying images.

### **Disclaimer (Artificial intelligence)**

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc. have been used during the writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

1.

2.

3

## References

1. Chidozie Declan Iwu, Chinwe Juliana Iwu-Jaja, Gastric Cancer Epidemiology:

Current Trend and Future Direction; *Hygiene* 2023, 3(3), 256-268; <https://doi.org/10.3390/hygiene3030019>

2. Qin J, Liu M, Ding Q, Ji X, Hao Y, Wu X et al. The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells. *Mol Cell Biochem* 2014; 395:99–107.
3. Bing HB, El Hajj N, Sittler S, Lammert N, Barnes R, Ehrig AM. Gastric cancer: classification, histology and application of molecular pathology. *J Gastrointest Oncol* 2012; 3:251–261.
4. Das G, Bhutia KD, Purkayastha J, Talukdar A. Early-Onset Gastric Cancer from a Geographic Area of High Gastric Cancer Incidence in North-East India: a Retrospective Study. *Indian J Surg Oncol*. 2023 Jun;14(2):308-311. doi: 10.1007/s13193-022-01675-8. Epub 2022 Oct 28. PMID: 37324311; PMCID: PMC10267022
5. Ilic M, Ilic I. Epidemiology of stomach cancer. *World J Gastroenterol*. 2022 Mar 28;28(12):1187-1203. doi: 10.3748/wjg.v28.i12.1187. PMID: 35431510; PMCID: PMC8968487.
6. Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. *J Cell Physiol*. 2019 Feb;234(2):1313-1325. doi: 10.1002/jcp.27172. Epub 2018 Sep 7. PMID: 30191996.
7. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med*. 2012 Jun; 366(26):2455–65.
8. Yong-Quan Chu, Zai-Yuan Ye, Hou-Quan Tao, Yuan-Yu Wang, and Zhong-Sheng Zhao;; Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma, *World journal of gastroenterology* 2008 Apr 7; 14(13): 1990–1996.
9. Menghui Wang and Chuan Xie, DNA Damage Repair and Current Therapeutic Approaches in Gastric Cancer: A Comprehensive Review, *Frontier Genetics*; 2022; 13: 931866. Published online 2022 Aug 12.

10. Yan-Shen Shan, Hui-Ping Hsu, Ming-DergLai, Yu-Hsuan Hung, Chih-Yang Wang, Meng-Chi Yen, and Yi-Ling Chen, Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer; *Oncol Lett.* 2017 Oct; 14(4): 4517–4526.  
Published online 2017 Aug 9.
11. Moonsik Kim and An Na Seo , Molecular Pathology of Gastric Cancer; *Gastric Cancer Journal* 2022 Oct; 22(4): 273–305.
12. Wu Y, Cao D, Qu L, et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. *Oncotarget* 2017; 8:64066–82.
13. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exper Med.* 2000; 192(7):1027–34. <https://doi.org/10.1084/jem.192.7.1027> (PubMed PMID: 11015443; PubMed Central PMCID: PMC2193311).
14. Songül Şahin,<sup>1,\*</sup> Şebnem Batur,<sup>2</sup> Övgü Aydın,<sup>2</sup> Tülin Öztürk,<sup>2</sup> Akif Turna,<sup>3</sup> and Büge Öz,<sup>2</sup>  
Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis ; *Balkan Medical Journal*, 2019 May; 36(3): 184–189. Published online 2019 May 10.
15. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. *Lab Invest* 2014; 94:107–16
16. Marion Peyressatre,† Camille Prével,† Morgan Pellerano, and May C. Morris\*, Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors; *Cancers(Basel)* , 2015 Mar; 7(1): 179–237, Published online 2015 Jan
23. doi: [10.3390/cancers7010179](https://doi.org/10.3390/cancers7010179)

PMCID: PMC4381256

17. Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. *Nat Rev Cancer* 7: 558-572, 2011.
18. Peng Gao, Geng-Yin Zhou, Yuan Liu, Jin-Song Li, Jun-Hui Zhen, and Yin-Ping Yuan,  
Alteration of cyclin D1 in gastric carcinoma and its clinicopathologic significance ;  
*World. J.of Gastroenterology* 2004 Oct 15; 10(20): 2936–2939. Published online 2004 Oct 15. doi: [10.3748/wjg.v10.i20.2936](https://doi.org/10.3748/wjg.v10.i20.2936)
19. Aoyagi K, Koufujii K, Yano S, Murakami N, Terasaki Y, et al. Immunohistochemical study on the expression of cyclin D1 and E in gastric cancer. *The Kurume medical journal.* 2000;47(3):199-203. DOI: [10.2739/kurumemedj.47.199](https://doi.org/10.2739/kurumemedj.47.199).
20. Hirata Y, Maeda S, Mitsuno Y, et al. Helicobacter pylori activates the cyclin D1 gene through mitogen-activated protein kinase pathway in gastric cancer cells. *Infect Immun.* 2001;69: 3965–3971.
21. Montalto, F.I.; De Amicis, F. Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. *Cells* **2020**, *9*, 2648. <https://doi.org/10.3390/cells9122648>
22. Wang C, Li Z, Fu M, Bouras T, Pestell RG. Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential. *Cancer Treat Res.* 2004;119:217–37
23. Ubukata Y, Ogata K, Sohda M, et al. Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer. *Oncology* 2021;99:15–22.
24. Li J, Chen L, Xiong Y , Zheng X et al , Knockdown of PD-L1 in human gastric cancer cells inhibits tumor progression and improves the cytotoxic sensitivity to CIK therapy *Cell PhysiolBiochem* ;2017 Feb 41: (3) : 907-20

25. Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, . PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. *Cancer Sci.* 2018 Jan;109(1):43–53.
26. Saha AK, Maitra S, Hazra SC. Epidemiology of gastric cancer in the gangetic areas of West Bengal. *ISRN Gastroenterol* 2013;2013:823483.
27. Machida-Montani A, Sasazuki S, Inoue M, Natsukawa S, Shaura K, Koizumi Y, et al. Association of Helicobacter pylori infection and environmental factors in non-cardia gastric cancer in Japan. *Gastric Cancer* 2004;7:46-53.
28. Lee YY, Derakhshan MH. Environmental and lifestyle risk factors of gastric cancer. *Arch Iran Med* 2013;16:358-65.
29. Ali Reza Yusefi , Kamran Bagheri Lankarani , Peivand Bastani , Maryam Radinmanesh , Zahra Kavosi<sup>3</sup> ,Risk Factors for Gastric Cancer: A Systematic Review *Asian Pacific Journal of Cancer Prevention*, 2018 :Vol 19(5) pg 591-603.
30. Giovanni Maconi, Gianpiero Manes, and Gabriele Bianchi Porro ,Role of symptoms in diagnosis and outcome of gastric cancer *World J. of Gastreterology*, 2008 Feb 28; 14(8): 1149–1155.
31. LitingLv, Xiao Liang, Dan Wu,Feng Wang, Yan Zhang, Hui Cang, XiongweiDeng, and Mei Li,Is cardia cancer a special type of gastric cancer? A differential analysis of early cardia cancer and non-cardia cancer; *J Cancer* 2021; 12(8): 2385–2394.
32. Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M. et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. *JAMA Oncol* 4, e180013

33. Xing, X.; Guo, J.; Ding, G.; Li, B.; Dong, B.; Feng, Q.; Li, S.; Zhang, J.; Ying, X.; Cheng, X.; et al. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. *Oncoimmunology* 2018, 7, e1356144.
34. Jun S-Y, Hong S-M, Jang K-T. Prognostic Significance of Cyclin D1 Expression in Small Intestinal Adenocarcinoma. *Cancers*. 2023; 15(20):5032.  
<https://doi.org/10.3390/cancers>
35. Ibrahim, H.M., AbdElbary, A.M., Mohamed, S.Y. *et al.* Prognostic Value of Cyclin D1 and CD44 Expression in Gastric Adenocarcinoma. *J GastrointestCanc* **50**, 370–379 (2019). <https://doi.org/10.1007/s12029-018-0079-2>
36. Go S-I, Ko GH, Lee WS, Lee J-H, Jeong S-H, Lee Y-J, Hong SC, Ha WS. Cyclin D1 Serves as a Poor Prognostic Biomarker in Stage I Gastric Cancer. *Current Issues in Molecular Biology*. 2022; 44(3):1395-1406.  
<https://doi.org/10.3390/cimb44030093>
37. Javed A, Yarmohammadi M, Korkmaz KS, Rubio-Tomás T. The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer. *International Journal of Molecular Sciences*. 2023; 24(3):2848.  
<https://doi.org/10.3390/ijms24032848>
38. Xing, X.; Guo, J.; Ding, G.; Li, B.; Dong, B.; Feng, Q.; Li, S.; Zhang, J.; Ying, X.; Cheng, X.; et al. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. *Oncoimmunology* 2018, 7, e1356144
39. Anna Junttila 1 , Olli Helminen1 , Juha P. Väyrynen et al, Immunophenotype based on inflammatory cells, PD-1/PDL1 signalling pathway and M2 macrophages predicts survival in gastric cancer ; *British Journal of Cancer* (2020) 123:1625–1632;  
<https://doi.org/10.1038/s41416-020-01053-7>
40. Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. *Gut*. 2017 May;66(5): 794–801.

41. Shen B, Qian A, Lao W, Li W, Chen X, Zhang B, . Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer. *Cancer Manag Res.* 2019 May;11:3909–19
42. Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, . CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. *Nature.* 2017 Sep;549(7670):101–5. Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, . Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. *Gastric Cancer.* 2018 Jan;21(1):31–40.
43. Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, . Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. *Gastric Cancer.* 2018 Jan;21(1):31–40.
44. Dislich B, Mertz KD, Gloor B, Langer R. Interspatial Distribution of Tumor and Immune Cells in Correlation with PD-L1 in Molecular Subtypes of Gastric Cancers. *Cancers.* 2022; 14(7):1736.
45. Renata D'Alpino Peixoto, Maria Cecilia Mathias-Machado, Alexandre Jácome, Mariana GilJoão et al. PD-L1 testing in advanced gastric cancer—what physicians who treat this disease must know—a literature review ; *J Gastrointest Oncol.* 2023 Jun 30; 14(3): 1560–1575
46. Yamashita, K., Iwatsuki, M., Harada, K. et al. Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?. *Br J Cancer* 121, 278–280 (2019). <https://doi.org/10.1038/s41416-019-0515-5>
47. BirgidSchoemig-Markiefka, Jana Eschbach, Andreas H. Scheel, Aylin Pamuk, Josef Rueschoff e Optimized PD-L1 scoring of gastric cancer al ; *Gastric Cancer.* 2021; 24(5): 1115–1122

UNDER PEER REVIEW